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ABSTRACT
This report aims to review a case of breast implant-associated anaplastic large cell lymphoma
(BIA-ALCL) by comparing the patient’s course with the current literature.
BIA-ALCL is a specific type of T-cell lymphoma that can develop after breast implantation, but has only
recently been recognized within the last decade. Although overall rare, certain types of breast implants
have increased association with developing subsequent lymphoma. This case occurred after mastectomy
with breast reconstruction for unilateral invasive ductal carcinoma with a textured, saline Allergan breast
implant. BIA-ALCL manifested and was symptomatic nine years after implantation.
Keywords: breast implant, ALCL, textured implant, lymphoma

BACKGROUND

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is rare, but as the number of
reported cases grows, so has its global recognition. The first case of breast implant-associated anaplastic
lymphoma was reported in 1997 by Keech and Creech with a McGhan (now Allergan) textured saline
implant.1 In 2011, after 34 published cases, the U.S. Food and Drug Administration (FDA) issued a safety
communication to announce the possibility of an association between breast implants and developing
anaplastic large cell lymphoma in the scar capsule adjacent to the implant.2 In 2016, the World Health
Organization officially recognized an association between breast implants and ALCL from approximately
258 reported cases.3 In July of 2019, the FDA requested Class I recall of the Allergan Natrelle BIOCELL
Textured Products.4 Allergan subsequently announced a voluntary worldwide recall of their textured saline
and silicone implants, as well as their tissue expanders. By October 2019, the American Society of Plastic
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Surgeons confirmed 809 cases of BIA-ALCL worldwide.5 The exact number of BIA-ALCL has been
difficult to determine because of underreporting, lack of awareness, lack of worldwide breast implant sales
data, and fear of litigation.6,7 We will review a specific case of BIA-ALCL after Allergan textured saline
implant breast reconstruction.
Case description
A 73-year-old Caucasian woman with a past medical history of papillary thyroid carcinoma and right
breast cancer presented with chest pain. She had been diagnosed eight years prior with invasive ductal
carcinoma of her right breast (ER/PR positive, HER2 negative). For treatment, she underwent a right
simple mastectomy with reconstruction using a permanent Allergan textured, shaped saline implant. Based
on her staging and pathology, no adjuvant therapy nor hormonal therapy was indicated. Her last screening
mammogram had been two years ago of her left breast that showed scattered fibroglandular densities,
interpreted as breast imaging reporting and data system – 1 (BI-RADS-1) normal.
At presentation, her chest pain was described as sharp and pleuritic, accompanied by chest congestion,
wheezing, and a non-productive cough. Acute coronary syndrome and respiratory workup were negative,
and she was discharged home with five days of prednisone therapy and a refill of her home albuterol
inhaler. A month later, she returned with shortness of breath and swelling of her right breast, extending
along her neck. Upon examination, she had fluctuance and a hard palpable rind consistent with a Baker
Grade 3 capsular contracture around her saline implant. A computed tomography of her chest revealed a
loculated fluid attenuation around her right breast implant without axillary or mediastinal
lymphadenopathy Figure 1.
Two days later, she underwent ultrasound-guided aspiration of the fluid collection to remove 650 cc of
straw-colored fluid. Initial flow cytometry analysis of the peri-implant fluid demonstrated 74%
lymphocytes without immunophenotypic evidence of monotypic B-cell or aberrant T-cell population.
After discussion with the patient, it was recommended that she undergo removal of the implant for
suspected ALCL due to the abnormal presence of lymphocytes in her periprosthetic seroma.
Approximately one month later, she underwent surgical removal of her right breast implant with en bloc
capsulectomy and drain placement. The fluid and capsule specimens were sent to a tertiary center for
further analysis. Cytologic analysis revealed atypical cells with pleomorphic nuclei that stained positive
for CD30, EMA, CD45, weakly CD3, and negative for AE1/3 and ALK (Figures 2, 3 and 4). These results
were concerning for a lymphoproliferative process, specifically BIA-ALCL.
After drain removal, she had a PET-CT scan that revealed post-surgical inflammatory changes in the right
chest wall without abnormal uptake elsewhere (Figures 5 and 6 ). TNM staging of BIA-ALCL was
determined to be T2N0M0, confined to the effusion and capsule. She required no further treatment. She
has denied further symptoms and has suffered no disease recurrence for two years.
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DISCUSSION

BIA-ALCL is a unique type of non-Hodgkin’s lymphoma. It is a T-cell lymphoma that develops in the scar
capsule or fluid surrounding the breast implant consisting of large pleomorphic cells staining CD30
positive and ALK-1 negative. These lack anaplastic lymphoma kinase expression or genetic abnormalities
involving systemic anaplastic lymphoma kinase at chromosome 2q23.6 Because the lymphoma cells are
initially contained inside the fibrous scar capsule that surrounds the breast implant, patients often present
with breast pain, enlargement, asymmetry, mass, rash, and/or hardening of the breast caused by capsular
contracture.8,9 Most commonly, patients present with a late-onset, persistent seroma with breast pain and
swelling at least 1 year after, but typically 9-10 years after placement of a textured breast implant.7,9–11
One systematic review of BIA-ALCL in 2017 noted that 66% patients presented with an isolated late-onset
seroma and 8% with an isolated new breast mass.12
When suspecting BIA-ALCL, National Comprehensive Cancer Network guidelines recommend imaging
with ultrasound or MRI of the breast, which can reveal an effusion or seroma around the implant that can
be sampled by fine needle aspiration.7 If it presents as a mass, core needle biopsy or incisional biopsy
should be obtained. The histopathological workup should include cytology, flow cytometry, and
immunohistochemistry for CD30 and ALK markers. If pathology reveals strong CD30 positivity and
EMA positivity, this should raise suspicion of BIA-ALCL, especially if ALK is negative.8 ALCL can be
detected with CD30, as it is a surface protein from the TNF receptor family not found in benign
periprosthetic seromas.Per the 2016 World Health Organization classification of lymphoid neoplasms,
diagnosis for BIA-ALCL is made by clinical correlation with immunohistochemical analysis of tumor
cells expressing CD30+, ALK-, having large anaplastic morphology on cytology, and demonstrating a
single T-cell clone.3 TNM staging is classified as IA (35-70%, effusion only), IB (3-11%, confined to
effusion or layer on luminal side of capsule), IC (8-13%, early capsule infiltration), IIA (8-25%, cell
aggregates or sheets infiltrating the capsule), IIB (3-5%, lymphoma infiltrates beyond capsule), and III
(3-9%, lymph node involvement) to stage IV (1-2%, metastasis).7,13
In 2017, the first U.S. retrospective review by Doren et al. attempted to determine the risk of developing
BIA-ALCL and discovered that there seemed to be higher risk of developing primary breast ALCL with a
textured implant than in the general population without such an implant.6 Regarding the most recent
estimation of total reports of BIA-ALCL worldwide, 481 of the 573 cases have occurred with the use of
Allergan (formerly McGhan) textured implants and has resulted in 12 deaths.4
It is not currently known why there is an association between textured breast implants and ALCL, but
there are several theories regarding pathogenesis. Chronic inflammation from the implant itself may be
triggering the immune system, and over many years, may increase the risk of malignant
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transformation.14,15 Texturing the implant’s surface can result in residual silicone particulate. This
combined with a bacterial antigen may be promoting the activation and proliferation of T cells that are
encouraged with a textured implant.15,16 Activation of the JAK/STAT pathway may also suggest that
investigation into possible genetic involvement may be needed. In a review of twenty-six BIA-ALCL
samples, there was a high bacterial load with bacteria biofilm in both BIA-ALCL and nontumor capsule
samples, but the microbiome of the BI-ALCL samples showed a greater proportion of Ralstonia species
and less Staphylococcus species, suggesting an infectious contributing cause.17
Primary treatment is en bloc capsulectomy to remove the breast implant and the entire fibrous capsule as
one piece, along with any suspicious masses or lymph nodes.18 Bone marrow biopsy may be obtained if
there is concern for local invasion or metastasis.7 After surgical excision, the patient should be followed
every 3-6 months for two years and consider CT or PET/CT every 6 months for surveillance of disease
recurrence. If residual disease exists or if the lymphoma is advanced (stage IIB-IV), systemic therapy with
Brentuximab vedotin, anthracycline-based systemic ALCL regimens, and/or radiation therapy should be
discussed, based on results from the ECHELON-2 trial.11,19,20 ECHELON-2 compared brentuximab
vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) therapy versus cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) therapy for the treatment of CD30-positive peripheral
T-cell lymphomas and concluded that A+CHP therapy was superior to CHOP with improvement in overall
survival.19 BIA-ALCL is surgically curable with good prognosis and high survival rates when diagnosed in
early stages.6,11
The case discussed here had the expected presentation and course of BIA-ALCL. She presented nine years
after her unilateral mastectomy and breast reconstruction with an Allergan textured, saline implant. Her
initial symptoms were chest pain and shortness of breath, followed by fullness and hardening of the
capsule around her saline implant. Diagnosis was made by analysis of the periprosthetic fluid and tissue
analysis after capsulectomy.
Efforts should be made to educate and inform those patients who have already received reconstruction
with textured breast implants. With increased awareness, detecting additional cases will allow for further
reviews to evaluate pathophysiology for future breast implant research. If a case is confirmed, it should be
reported to the FDA through the Adverse Event Reporting program. BIA-ALCL should be treated by
removing the fibrous capsule and implant using an en bloc oncologic resection method. The capsule
should be further examined for confirmation of the diagnosis and staging to guide management.
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Figure 1 Computed tomography scan with peri-implant fluid.
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Figure 2 Right breast capsulectomy excision specimen. The tumor cells (circled) are not mass-forming. Abundant
background fibrosis and inflammation (H&E 10x).

https://rdw.rowan.edu/crjcsm/vol4/iss1/10
DOI: 10.31986/issn.2578.3343_vol4iss1.10

126

Tan et al.: Breast Implant-Associated Anaplastic Large Cell Lymphoma

Figure 3 Atypical, pleomorphic cells (H&E 40x).
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Figure 4 CD30 positive stain.
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Figure 5 Computed tomography after en bloc capsulectomy in axial section.
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Figure 6 Positron emission tomography-computed tomography after en bloc capsulectomy in coronal section
showing no metastatic disease.
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